Compare EPR Properties (EPR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Gilead Sciences, Inc. — how do they compare? EPR Properties trades at $54.41 (market cap $4.17B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 43.7× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Gilead Sciences, Inc. for 111 Days on average.
| EPR | GILD | |
|---|---|---|
Market Cap | $4.17B | $182.40B |
Volume | 992,716 | 4,469,821 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $155.80 |
52-Week Low | $48.71 | $116.74 |
Typical Hold Time | 45 Days | 111 Days |
Enterprise Value | $7.68B | $205.46B |
Dividend Yield | 6.84% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.
EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
